Research · 9 min read
What Happens to Your GLP-1 Cost When the Dose Goes Up
Approved labeling for these medications describes a stepwise escalation, and many programs price by strength. That combination means the figure you pay in month one is often not the figure you pay in month six.
Key takeaways
- Many programs price by strength, so a headline figure attached to the starting dose describes the first weeks rather than the treatment.
- Zepbound's labeling starts at 2.5 mg weekly for four weeks and increases in 2.5 mg increments after at least four weeks, to a maximum of 15 mg weekly.
- Wegovy's injection labeling starts at 0.25 mg weekly for four weeks and titrates every four weeks; it is also labeled as a tablet with its own escalation.
- Some programs hold one price across every strength, which is a real difference and rarely a headline.
- With a compounded vial, escalation can show up as more frequent shipments rather than a higher line item.
- FDA has reported hospitalizations from dosing errors with compounded injectable semaglutide, involving varying concentrations and doses described in units.
The answer, before the detail
Cost moves with dose in most programs, and it moves upward. A price quoted at the lowest strength describes the beginning of treatment rather than the treatment.
The reason is structural rather than sneaky. These medications are supplied and labeled in separate strengths, and a program that buys and dispenses by strength usually prices by strength too.
Some programs hold one price across every strength, which is a genuine difference between offerings and rarely the first thing on a homepage. Whether a program does this is a question with a written answer, and it is worth getting before enrolling.
What the approved labels actually describe
Zepbound's labeling sets a starting dosage of 2.5 mg once weekly for four weeks, then increases in 2.5 mg increments after at least four weeks until the maintenance dosage is reached. It lists a maximum recommended dosage of 15 mg once weekly and names treatment response and tolerability as the things to weigh when selecting a maintenance dosage.
Wegovy's injection labeling starts at 0.25 mg once weekly for four weeks, then follows an escalation schedule titrating every four weeks toward a maintenance dosage. The label lists single-dose presentations at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg and 7.2 mg.
Wegovy is also labeled as a tablet, initiated at 1.5 mg once daily for 30 days and titrated every 30 days, with tablet strengths of 1.5 mg, 4 mg, 9 mg and 25 mg. The oral form has its own escalation and its own set of strengths.
Your own schedule is a decision for your prescriber, and the instructions that govern it are in the labeling that comes with your carton. What the labels establish for a cost conversation is simpler: escalation is the expected shape of treatment, and each step is a distinct labeled strength.
Why a step costs more in one program and nothing in another
A program that prices per strength passes the ladder through to you. Each escalation is a new line on the invoice, and the cost curve rises for months before it settles.
A program that prices per month regardless of strength absorbs the ladder. The first month and the sixth month cost the same, which makes a long treatment easier to plan even when the headline figure looks higher.
A third pattern sits between them, where price holds across the lower strengths and steps once at a higher one. That is easy to miss because the first two or three months behave like a flat price.
None of these is inherently better value. They are different shapes, and a comparison that ignores the shape compares two programs at the only point where they happen to look alike.
The cost of staying where you are
Not every escalation happens on schedule. Labeling for these products describes selecting a maintenance dosage with response and tolerability in mind, and people settle at different points along the ladder.
That has a direct financial consequence in a strength-priced program. Somebody who settles at a lower strength pays a lower recurring figure than the ladder's top step, and somebody who reaches the maximum pays that top figure every month.
So a single projected cost is the wrong output. A range across the strengths a program actually prices is the honest one, and any program pricing this way can supply the whole ladder on request.
Ask for the figure at every strength before you enroll, not at the strength you start on. That is one email, and it converts a headline into something you can plan against.
Compounded pricing changes the question rather than removing it
A compounded preparation is not supplied as a labeled pen with fixed increments. It typically arrives as a vial at a concentration the pharmacy selected, and the person injecting measures a volume from it.
That changes how price scales. Cost may follow the total quantity in the vial rather than a labeled strength, so escalation can show up as a shorter interval between shipments rather than as a higher line item.
It also introduces a safety consideration that has nothing to do with money. FDA has reported adverse events, some requiring hospitalization, related to dosing errors with compounded injectable semaglutide, arising both from patients measuring incorrect doses and from health care professionals miscalculating them.
FDA described the mechanics in detail. Concentrations vary between compounders and a single compounder may offer several. Instructions may describe doses in units, whose volume depends on the concentration. In the majority of reports, patients drew more than the prescribed dose from a multiple-dose vial, in some cases five to twenty times the intended amount.
So with a compounded product, ask what concentration is being supplied and what changes when the dose changes. That question is about both the invoice and the syringe.
How to price a year instead of a month
Start by asking whether the program prices by strength at all. A yes turns every later question into arithmetic; a no ends the exercise quickly.
If it prices by strength, get the figure at each one. Then build two totals: one where you settle at a lower strength and one where you reach the program's top-priced step.
Add anything required alongside the medication, since a required fee usually does not move with dose and therefore weighs more heavily at the lower strengths.
Then ask what happens between steps. Whether a partly used supply carries over, whether a step change resets a commitment, and whether an increase can happen mid-cycle are all answerable in writing, and all of them move a real invoice.
Frequently asked questions
Does every program charge more at a higher dose?
No, and that is one of the more consequential differences between programs. Some price per strength, so each escalation appears as a higher recurring charge. Some hold one price across every strength they supply. Some hold a price across the lower strengths and step once higher up, which looks flat for the first few months. Ask which pattern applies and get the figure at each strength before enrolling, rather than the figure at the strength you start on.
Why is a low headline price attached to the starting dose?
Because the starting strength is the one nearly everyone begins on, so it is the widest-reaching low number a program can advertise. Approved labeling describes escalation as the expected shape of treatment. Zepbound's labeling starts at 2.5 mg once weekly for four weeks and increases in 2.5 mg increments after at least four weeks, up to a maximum recommended dosage of 15 mg weekly. Wegovy's injection labeling starts at 0.25 mg once weekly for four weeks and titrates every four weeks toward a maintenance dosage.
How does pricing work for a compounded vial?
Differently, because there is no labeled pen with fixed increments. A compounded preparation typically arrives as a vial at a concentration the pharmacy chose, and cost may track the quantity in the vial rather than a labeled strength. An escalation can therefore show up as more frequent shipments rather than as a higher line item. Ask what concentration is supplied, how much arrives per shipment, and what changes when the dose changes.
What should I ask before the first escalation?
Ask for the price at each strength the program supplies, in writing. Ask whether a change in dose can happen mid-cycle and what happens to the current billing period. Ask whether a partly used supply carries over or is discarded, and whether a step change resets any commitment. Ask whether a required fee moves with the dose or stays flat. Those answers turn a starting figure into a cost you can plan a year around.
Is a higher dose always where treatment ends up?
The labels do not describe it that way. Zepbound's labeling names treatment response and tolerability as the considerations when selecting a maintenance dosage, and lists more than one maintenance option. People settle at different points, which is exactly why a single projected cost is misleading and a range across the priced strengths is not. Dose decisions belong to you and your prescriber, and the schedule is in the labeling that arrives with your medication.